

RECEIVED  
CENTRAL FAX CENTER

JUL 08 2008

*Johnson & Johnson*3210 Merryfield Row  
San Diego, California 92121-1126  
Phone: (858) 320-3406  
Fax: (858) 784-3044**FACSIMILE COVER SHEET**

Date: July 8, 2008

To: Commissioner for Patents  
Attention: Examiner Riggs, Art Unit 1631  
Of: United States Patent and Trademark Office  
Fax No.: 571-273-8300

From: Linda S. Evans

Total Pages (including this page): 10

Re: Patent Application No. 10/579,458, filed May 16, 2006  
Applicant: Vitiello et al.  
Attorney Docket No.: PRD2091US-PCT

---

Certificate of transmission:

The undersigned certifies that the accompanying Amendment And Response To Office Action is being transmitted to the above-referenced fax number on the above-identified date.

  
Linda S. Evans (Reg. No. 33,873)

---

**CONFIDENTIALITY NOTICE:** This facsimile transmission, including this cover sheet and any documents that may accompany it, contains information from Johnson & Johnson intended only for the use of the individual or entity to which it is addressed, which may contain information that is privileged, confidential, and/or otherwise exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, any disclosure, dissemination, distribution, copying or other use of this communication or its substance is prohibited. If you have received this communication in error, please call us "collect" to arrange for the destruction of the communication or its return to us at our expense. Thank you.

RECEIVED  
CENTRAL FAX CENTER

JUL 08 2008

*Johnson & Johnson*3210 Merryfield Row  
San Diego, California 92121-1126  
Phone: (858) 320-3406  
Fax: (858) 784-3044**FACSIMILE COVER SHEET**

Date: July 8, 2008

To: Commissioner for Patents  
Attention: Examiner Riggs, Art Unit 1631  
Of: United States Patent and Trademark Office  
Fax No.: 571-273-8300

From: Linda S. Evans

Total Pages (including this page): 10

Re: Patent Application No. 10/579,458, filed May 16, 2006  
Applicant: Vitiello et al.  
Attorney Docket No.: PRD2091US-PCT

---

Certificate of transmission:

The undersigned certifies that the accompanying Amendment And Response To Office Action is being transmitted to the above-referenced fax number on the above-identified date.

  
Linda S. Evans (Reg. No. 33,873)

---

**CONFIDENTIALITY NOTICE:** This facsimile transmission, including this cover sheet and any documents that may accompany it, contains information from Johnson & Johnson intended only for the use of the individual or entity to which it is addressed, which may contain information that is privileged, confidential, and/or otherwise exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, any disclosure, dissemination, distribution, copying or other use of this communication or its substance is prohibited. If you have received this communication in error, please call us "collect" to arrange for the destruction of the communication or its return to us at our expense. Thank you.

RECEIVED  
CENTRAL FAX CENTER  
JUL 08 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Vitiello et al.

Atty. Docket: PRD2091US-PCT

US National Phase of: PCT/US2004/038648

Art Unit: 1631

International filing date: November 17, 2004

Examiner: Riggs II, Larry D.

U.S. Serial No.: 10/579,458

Confirmation No. 3414

For: Animal Models For The Systemic  
Inflammatory Response To Infection

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT AND RESPONSE TO OFFICE ACTION**

Sir:

This is a reply to the Office Action mailed April 8, 2008. In the event any fees are required for the filing of this response, including in connection with any necessary extension of time (for which Applicant hereby petitions), please charge such fees to Deposit Account No. 10-0750.

Favorable reconsideration of the application is requested in view of: the amendments to the specification, which begin on page 2 of this response; the amendments to the claims, which commence on page 3; and the accompanying remarks, which begin on page 7.